SAN DIEGO, June 28, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (“Apricus Bio”) (Nasdaq:APRI) announced today that its marketing application for Vitaros®, indicated for the treatment of patients with erectile dysfunction (“ED”), has been accepted for review through the European Decentralized Procedure (“DCP”).
